Guggenheim analyst Yatin Suneja downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a $20 price target Published first on TheFly – ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...

In the digital realm, the guggenheim-bilbao.eus website recorded a total of 2.893.452 visits and 10.850.342 page views in ...

Investing.com -- Guggenheim named Madison Square Garden Sports Corp (NYSE:MSGS) its "best idea" for 2025 given strong secular ...

Guggenheim named MSG Entertainment (MSGE) as a best idea entering 2025. Shares have slid about 23% since fiscal Q1 earnings ...

With its stunning Frank Lloyd Wright design, the Guggenheim Museum is a piece of art in itself. Inside these rounded walls, ...

As previously reported, Guggenheim analyst Michael Morris initiated coverage of Reddit (RDDT) with a Buy rating and $210 ...

The Guggenheim's Orphism exhibition includes more than 90 artworks on display in its iconic rotunda, celebrating the 1910s ...

Naomi Beckwith, who holds a leadership role at the Guggenheim Museum in New York, said she would make navigating crises a ...

Guggenheim raised the firm’s price target on RH (RH) to $550 from $425 and keeps a Buy rating on the shares. Not only did RH meet the mid-point of its Q3 total demand revenue guidance, but management ...

Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the ...

But apparently they can also still surprise us. On Friday, according to a flurry of Korean reports, the Dodgers appear to ...